I think you may want to rethink this statement, because if the 336 was found invalid the stock price would most certainly have dropped significantly

What did actually happen with the stock price once the re-examination requests started arriving at the USPTO?

My paraphrasing of the apparent statement of fact, the re-cert/re-exam scenario has not been, and is not presently, the problem as to PTSC's lagging stock price, was to question its accuracy.

If, as you say, the price would have dropped significantly had a patent been found invalid, there must surely have been an ongoing negative impact on the price during re-examinations?

.

.

.

Be well